Henrik Oerum

Dr. Henrik Oerum is a member of the Scientific Advisory Board of Ceptur Therapeutics. He is the co-founder and the Chief Scientific Officer of Civi BioPharma and has previously founded 3 other oligonucleotide companies. Dr. Oerum has over 25 years of experience in the development and commercialization of oligonucleotide therapeutics, has authored >70 peer-reviewed publications, and has been listed as an inventor on numerous patents in the field. In 1993, he founded PNA Diagnostics A/S, where he was also the Chief Scientific Officer until 1999. During his tenure at PNA, the company was sold to Boehringer Mannheim (1994) and later to Hoffman-La Roche (1997). In 1996, Dr. Oerum cofounded Exiqon A/S, a nucleic acid diagnostics company that was floated on the Copenhagen Stock Exchange in 2007 (CSE: EXQ). In 2000, he co-founded the LNA-oligotherapeutics company Santaris Pharma A/S, where he served as Chief Scientific Officer and Vice President of Business Development until its acquisition by Roche in 2014. Thereafter, he worked for Roche Pharma as Global Head of RNA therapeutics until March 2016, where he left to pursue new opportunities, leading to his founding of CiVi. Dr. Oerum earned his M.Sc. in molecular biology from the Technical University of Copenhagen, his Ph.D. in molecular biology from the Medical University of Copenhagen, and he completed his postdoctoral studies at the Royal School of Pharmacy, Copenhagen, Denmark.